Global Cancer Technology

Global Cancer Technology

Early Stage

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Overview

Raised to Date: Raised: $107,000

Total Commitments ($USD)

Platform

Netcapital

Start Date

10/21/2019

Close Date

02/25/2020

Min. Goal
$10,000
Max. Goal
$107,000
Min. Investment

$1

Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$11,571,400

Rolling Commitments ($USD)

Status
Funded
Reporting Date

02/29/2020

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$849

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

San Diego, California

Company Website

Global Cancer Technology, with a post-money valuation of $11.6 million, is raising funds on NetCapital. It is an emerging medical technology company that may soon revolutionize cancer therapy. The technology of Global Cancer Technology is protected by several patents and is aimed at remote-controlled cancer drug delivery. Global Cancer Technology was founded by John P. Clark. The current round of crowdfunding has a minimum target of $10,000 and a maximum target of $107,000, and the proceeds will be used for pre-clinical work, research, marketing, commercialization, and general and administrative expenses. The technology of Global Cancer Technology was developed by scientists at Moores Cancer Center UC San Diego. Using the technology, the cancer drug will be attached to a nanocrystal scintillator and delivered to the body conveniently.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Global Cancer Technology 04/28/2022 Netcapital $26,682,636 $0 Equity - Common Not Funded RegCF
Global Cancer Technology 09/07/2021 Dalmore Group - $24,400 Equity - Common Funded RegA+
Global Cancer Technology 02/24/2020 Netcapital $11,571,400 $107,000 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Global Cancer Technology on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $11,571,400
Price per Share: $1.00

Follow company

Follow Global Cancer Technology on Netcapital
View on Netcapital (Closed)
Deal Analytics
Deal Considerations

Buy Global Cancer Technology's Deal Report

Warning: according to the close date for this deal, Global Cancer Technology may no longer be accepting investments.

Global Cancer Technology Deal Report

Get KingsCrowd’s comprehensive report on Global Cancer Technology including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Global Cancer Technology is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Global Cancer Technology deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge